Adocia (ADOC) Stock Overview
A clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ADOC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Adocia SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €7.69 |
| 52 Week High | €11.10 |
| 52 Week Low | €2.86 |
| Beta | 0.31 |
| 1 Month Change | -6.11% |
| 3 Month Change | 103.44% |
| 1 Year Change | 40.33% |
| 3 Year Change | 92.97% |
| 5 Year Change | 2.95% |
| Change since IPO | -50.36% |
Recent News & Updates
Recent updates
Adocia SA's (EPA:ADOC) Shares Climb 39% But Its Business Is Yet to Catch Up
Jul 24
Revenues Not Telling The Story For Adocia SA (EPA:ADOC) After Shares Rise 31%
May 10Estimating The Intrinsic Value Of Adocia SA (EPA:ADOC)
Oct 24Adocia SA's (EPA:ADOC) Shareholders Might Be Looking For Exit
Dec 20Is Adocia (EPA:ADOC) A Risky Investment?
May 21Is Adocia (EPA:ADOC) Using Debt In A Risky Way?
Dec 14
Shareholder Returns
| ADOC | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 5.3% | 14.7% | 3.0% |
| 1Y | 40.3% | 19.6% | 5.4% |
Return vs Industry: ADOC exceeded the French Biotechs industry which returned 17.2% over the past year.
Return vs Market: ADOC exceeded the French Market which returned 5.8% over the past year.
Price Volatility
| ADOC volatility | |
|---|---|
| ADOC Average Weekly Movement | 19.5% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in FR Market | 10.6% |
| 10% least volatile stocks in FR Market | 2.1% |
Stable Share Price: ADOC's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ADOC's weekly volatility has increased from 14% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 75 | Olivier Soula | www.adocia.com |
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company’s clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of prandial insulin with pramlintide, as well as M1Pram, a combination of insulin M1 and pramlintide.
Adocia SA Fundamentals Summary
| ADOC fundamental statistics | |
|---|---|
| Market cap | €140.24m |
| Earnings (TTM) | -€9.71m |
| Revenue (TTM) | €12.88m |
Is ADOC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADOC income statement (TTM) | |
|---|---|
| Revenue | €12.88m |
| Cost of Revenue | €20.09m |
| Gross Profit | -€7.21m |
| Other Expenses | €2.50m |
| Earnings | -€9.71m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.53 |
| Gross Margin | -55.98% |
| Net Profit Margin | -75.42% |
| Debt/Equity Ratio | -382.8% |
How did ADOC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 12:58 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Adocia SA is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Welford | Jefferies LLC |
| Seamus Fernandez | Leerink Partners LLC |
| Nazibur Rahman | Maxim Group |